Sign In
Buy BEAM
$25.52
-0.97 (-3.66%)
At Close: Jul 31, 2026
Earnings Preview: Beam Therapeutics Inc. (BEAM) Q4 Earnings Expected to Decline
11:06am, Tuesday, 20'th Feb 2024
Beam Therapeutics Inc. (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
06:46am, Thursday, 15'th Feb 2024
Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.
Analysts see over 50% gains in these 2 mid-cap biotech stocks
09:10am, Wednesday, 14'th Feb 2024
In recent years, emergency Covid vaccines have ushered in several groundbreaking innovations that have changed the way drugs are developed and health care is administered. Advancements in the treatmen
3 Biotech Stocks to Buy on the Dip: February 2024
07:35am, Wednesday, 07'th Feb 2024
Biotech investing is not for impatient investors. So why is it attractive to some investors?
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
06:30am, Monday, 05'th Feb 2024
CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man
Why Beam Therapeutics Stock Zoomed 17% Higher Today
06:21pm, Monday, 29'th Jan 2024
An analyst upgraded his recommendation on the biotech. He thinks it stands in front of an excellent opportunity in the treatment of an inherited disorder.
2 gene editing stocks to keep on your 2024 watchlist
08:23am, Tuesday, 23'rd Jan 2024
Gene therapy will get its share of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. NASDAQ: VRTX and CRISPR Therapeutics AG NASDAQ: CRSP CR
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
01:51pm, Tuesday, 16'th Jan 2024
Biotech stocks, and the sector in general, saw a widespread beat down over the past two years. Venture capital dried up, post-pandemic healthcare landscapes shifted, and regulatory clampdowns tightene
3 Stocks to Buy in the Booming Field of Gene Editing
04:38pm, Thursday, 11'th Jan 2024
The promise of gene editing is moving closer to being a reality. If you're an investor with a speculative appetite and appropriate risk tolerance, you may want to consider a long position in gene edi
BEAM Stock Rallies More Than 25% in 3 Months: What Next?
12:01pm, Wednesday, 03'rd Jan 2024
BEAM is making good progress with its lead pipeline candidate, BEAM-101, which is being developed for treating sickle cell disease. Also, the recent restructuring efforts are expected to reduce costs.
Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
06:30am, Tuesday, 02'nd Jan 2024
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man
3 Biotechs With Promising Gene Therapies in the Spotlight
09:47am, Wednesday, 13'th Dec 2023
The recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline.
CRISPR Gene Editing: Beam Therapeutics
04:36am, Thursday, 30'th Nov 2023
Beam Therapeutics focuses on base editing technology, which allows for precise changes at the DNA level and potentially reduces off-target effects. Base editing has the versatility to correct a wide r
The 3 Best Gene Editing Stocks on the Frontier of Medicine
05:43pm, Monday, 20'th Nov 2023
Some of the best gene editing stocks could soon see a massive boost. In just days, the U.S. FDA could approve the first gene-editing treatment of sickle cell disease (SCD) from CRISPR Therapeutics�
Is Beam Therapeutics Stock a Buy Now?
07:15am, Saturday, 18'th Nov 2023
Beam Therapeutics has what it needs to try to deliver its next clinical milestones. It's still running years behind other biotechs with its lead program.
